Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Completed

Conditions: Primary Hypercholesterolemia
Mixed Dyslipidemia

Interventions: Other: Inclisiran

First Posted Date: 2021-11-11

Last Posted Date: 2024-08-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 61

Registration Number: NCT05118230

Locations: 🇨🇳
Novartis Investigative Site, Qionghai, Hainan, China

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Radiation: 177Lu-PSMA-617
Radiation: 68Ga-PSMA-11
Other: Best supportive/best standard of care

First Posted Date: 2021-11-10

Last Posted Date: 2024-12-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 80

Registration Number: NCT05114746

Locations: 🇯🇵
Novartis Investigative Site, Kyoto, Japan

Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice

Terminated

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Other: brolucizumab

First Posted Date: 2021-11-09

Last Posted Date: 2024-10-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 302

Registration Number: NCT05112835

Locations: 🇬🇧
Novartis Investigative Site, Warwick, United Kingdom

A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease

Phase 2

Terminated

Conditions: Early Manifest Huntington Disease

Interventions: Drug: Branaplam
Drug: Placebo

First Posted Date: 2021-11-08

Last Posted Date: 2024-11-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 26

Registration Number: NCT05111249

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)

Completed

Conditions: Age-related Macular Degeneration (AMD)

Interventions: Drug: Brolucizumab

First Posted Date: 2021-11-08

Last Posted Date: 2021-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9261

Registration Number: NCT05111743

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Phase 4

Recruiting

Conditions: Non-Small Cell Lung Carcinoma

Interventions: Drug: Capmatinib 150 mg
Drug: Capmatinib 200 mg

First Posted Date: 2021-11-05

Last Posted Date: 2024-10-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT05110196

Locations: 🇮🇳
Novartis Investigative Site, Puducherry, India

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

Completed

Conditions: Age-related Macular Degeneration (AMD)

Interventions: Other: Aflibercept
Other: Ranibizumab
Other: Bevacizumab

First Posted Date: 2021-11-05

Last Posted Date: 2021-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 331541

Registration Number: NCT05110209

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

Conditions: Advanced Hormone Receptor Positive (HR+) Breast Cancer

First Posted Date: 2021-11-05

Last Posted Date: 2021-12-09

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05108740

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Phase 1

Recruiting

Conditions: Glioblastoma

Interventions: Drug: [177Lu]Lu-DOTA-TATE
Drug: [68Ga]Ga-DOTA-TATE
Other: Temozolomide
Other: Radiotherapy

First Posted Date: 2021-11-05

Last Posted Date: 2024-12-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT05109728

Locations: 🇺🇸
Dana Farber Cancer Institute Main Site, Boston, Massachusetts, United States
🇺🇸
University of Pittsburgh University of Pittsburgh 2, Pittsburgh, Pennsylvania, United States
🇺🇸
MD Anderson Cancer Center Uni of Te MDACC., Houston, Texas, United States

and more 2 locations

Managed Access Programs for LDK378, Ceritinib

Conditions: Anaplastic Lymphoma Kinase (ALK)- Positive Tumors
Non-small Cell Lung Cancer (NSCLC)

First Posted Date: 2021-10-29

Last Posted Date: 2024-02-08

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05100134

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy